drugset / Trial / NCT01529632

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01529632

Phase 3 Completed 193 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2012-05
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrrolate Small molecule 50 ug Inhaled
Comparator Indacaterol Other / unclassified 150 ug Inhaled
Subject QVA149 Other / unclassified 50 ug Inhaled
Subject QVA149 Other / unclassified 110 ug Inhaled